Hadar Goldvaser, MD
We post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Areas of Expertise
Conditions I Treat
- Breast cancers and conditions
- Hereditary cancers
- Young women with breast cancer
Get to Know Me
I am a medical oncologist specializing in breast cancer treatment and research. I see patients at Memorial Sloan Kettering Nassau. My goal is to provide professional and compassionate care to my patients and advance the field of breast cancer treatment through clinical research. I specialize in treating younger women with breast cancer and also people who are carriers of the BRCA gene mutations, which are associated with high risk of breast and ovarian cancer.
People with breast cancer often go through a complex journey to cope with the diagnosis. As their oncologist, I have the privilege to help them navigate through this journey aiming to provide the best possible care to each person.
Breast cancer treatment has evolved over the last few decades and patients now have many options. I focus on tailoring treatment to each person’s specific cancer diagnosis, coexisting health conditions, and their personal goals and life situations. I make sure my patients understand the potential benefits and risks of each treatment so we can work together to make decisions and help them receive the best possible cancer care. Working together with a diverse team of experts, including surgeons, radiologists, radiation oncologists, pathologists, and supportive care, I aim to provide comprehensive treatment.
I am also actively involved in researching breast cancer. My research focuses on better understanding common clinical dilemmas in the treatment of breast cancer. I have led several high-impact studies that aim to better quantify the risks of common breast cancer therapies and to define treatment effectiveness in different settings. Ultimately, these studies highlight the risk-benefit balance of different therapies for breast cancer and support more informed treatment choices. My research directly improves the quality of the clinical care I provide.
While newly developed therapies are available for BRCA carriers, they may also need to manage additional aspects such as coping with cancer at a younger age, decisions on risk-reducing surgery, fertility preservation, and long-term monitoring. I address each person’s unique needs to provide the best and most comprehensive care.
A breast cancer diagnosis can feel overwhelming, and the treatment may seem complex and difficult. I want to assure my patients that they are not alone. I am here for them at every step, to address their questions and concerns and sometimes just to listen and support. My dedication to the well-being of my patients extends beyond their diagnosis and treatment, and I am committed to doing everything I can for them.
I'm a breast medical oncologist, which is a cancer doctor who specializes in breast cancer.
- Assistant Attending Physician
Conditions I Treat
- Breast cancers and conditions
- Hereditary cancers
- Young women with breast cancer
Education
- MD, The Ruth and Bruce Rappaport Faculty of Medicine, Israel
Residencies
- Medical Oncology, Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, Israel
Fellowships
- Medical Oncology, Breast Cancer, Princess Margaret Cancer Centre, Canada
Awards and Honors
- Merit award, European Society of Medical Oncology (ESMO) Annual Congress (2018)
- First place in the Mimi and Charles Hollenberg Research Competition of the Department of Medicine of Mount Sinai Hospital and the University Health Network (2018)
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
HMO, EPO PPO, POS, Transplant
In Network Coverage Type
PPO
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
Supplemental
In Network Coverage Type
PPO, POS, HMO
In Network Coverage Type
POS, EPO, HMO
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
PPO, HMO
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
HMO, PPO
In Network Coverage Type
PPO EPO
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
PPO, HMO
In Network Coverage Type
State Government
In Network Coverage Type
PPO, POS, EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
HMO
City Employee Health Plans (Gold and Gold Care)
In Network Coverage Type
Supplemental
In Network Coverage Type
PPO/OAP
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
TBD
In Network Coverage Type
HMO/EPO
In Network Coverage Type
PPO, EPO
In Network Coverage Type
PPO, POS, HMO
In Network Coverage Type
State Government
In Network Coverage Type
State Government
In Network Coverage Type
PPO, HMO
In Network Coverage Type
PPO, POS
In Network Coverage Type
PPO, POS, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
Contact and Location
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
- Goldvaser H, Barnes TA, Šeruga B, Cescon DW, Ocaña A, Ribnikar D, Amir E. Toxicity of extended adjuvant therapy with aromatase inhibitors in early breast cancer: a systematic review and meta-analysis. JNCI: Journal of the National Cancer Institute. 2018 Jan;110(1):31-9.
- Goldvaser H, Korzets Y, Shepshelovich D, Yerushalmi R, Sarfaty M, Ribnikar D, Thavendiranathan P, Amir E. Deescalating adjuvant trastuzumab in HER2-positive early-stage breast cancer: a systemic review and meta-analysis. JNCI cancer spectrum. 2019 Jun;3(2):pkz033.
- Shepshelovich D, Tibau A, Goldvaser H, Molto C, Ocana A, Seruga B, Amir E. Postmarketing modifications of drug labels for cancer drugs approved by the US Food and Drug Administration between 2006 and 2016 with and without supporting randomized controlled trials. Journal of Clinical Oncology. 2018 Jun 20;36(18):1798-804.
- Korzets Y, Fyles A, Shepshelovich D, Amir E, Goldvaser H. Toxicity and clinical outcomes of partial breast irradiation compared to whole breast irradiation for early-stage breast cancer: a systematic review and meta-analysis. Breast cancer research and treatment. 2019 Jun 30;175:531-45.
- Mutai R, Barkan T, Moore A, Sarfaty M, Shochat T, Yerushalmi R, Stemmer SM, Goldvaser H. Prognostic impact of HER2-low expression in hormone receptor positive early breast cancer. The Breast. 2021 Dec 1;60:62-9.
Visit PubMed for a full listing of Dr. Goldvaser’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Members of the MSK Community often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community. These activities outside of MSK further our mission, provide productive collaborations, and promote the practical application of scientific discoveries.
MSK requires doctors, faculty members, and leaders to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public. Not all disclosed interests and relationships present conflicts of interest. MSK reviews all disclosed interests and relationships to assess whether a conflict of interest exists and whether formal COI management is needed.
Hadar Goldvaser discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2024 through disclosure submission in spring 2025). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].